High-dose-rate and pulsed-dose-rate brachytherapy in palliative treatment of head and neck cancers
High-dose-rate and pulsed-dose-rate brachytherapy in palliative treatment of head and neck cancers
复制标题
DOI：
10.1016/j.brachy.2011.09.006
复制
发表时间：
2012-03-01
期刊：
影响因子：
1.9
通讯作者：
Szyfter, Witold
中科院分区：
文献类型：
--
作者：
Bartochowska, Anna;Wierzbicka, Malgorzata;Szyfter, Witold
目的：本研究的主要目的是评估高剂量率近距离放射治疗（HDRBT）和脉冲剂量率近距离放射治疗（PDRBT）在局部或区域复发性头颈癌患者姑息治疗中的效果。详细目的是根据年龄、性别、原发和复发肿瘤定位、肿瘤大小、治疗方法（HDR/PDR）、主要治疗方法和放射剂量等不同参数对患者进行局部控制、生存率和并发症发生率的评估。方法与材料：PDRBT和HDRBT分别用于106例和50例患者。在8例患者中，BT手术与同期化疗联合进行。16例患者加行间质热疗。所有患者均在6个月内定期随访。评估局部控制、并发症和生存率。材料包括2002年1月至2008年11月在波兹南医科大学耳鼻喉科和大波兰癌症中心近距离放疗部接受HDRBT和PDRBT姑息治疗的头颈癌患者156例。结果：37.7%的患者在治疗结束后6个月完全缓解和部分缓解，而近距离放疗后12个月和24个月的生存率分别为40%和17%。总并发症发生率为35%。结论：我们的研究结果表明，HDRBT和PDRBT在局部或区域复发的头颈癌患者的姑息治疗中是一种安全的选择，这些患者在以前的放疗区域复发，不合格或拒绝手术。它具有良好的缓解效果，并发症发生率可接受。(C) 2012年美国近距离放射治疗学会。Elsevier Inc.出版。版权所有。
PURPOSE: The main purpose of the study was to assess the results of high-dose-rate brachytherapy (HDRBT) and pulsed-dose-rate brachytherapy (PDRBT) in the palliative treatment of patients with locally or regionally recurrent head and neck cancers. The detailed aims concerned the evaluation of these methods in the context of local control, survival, and complications rates in patients subgrouped by different parameters such as age, gender, primary and recurrent tumor localization, tumor size, treatment method (HDR/PDR), primary treatment method, and radiation dose applied.METHODS AND MATERIALS: PDRBT and HDRBT were used in 106 and 50 patients, respectively. In 8 patients, BT procedures were performed in combination with simultaneous chemotherapy. Sixteen patients were additionally treated with interstitial hyperthermia. All patients were regularly followed up within 6 months. Local control, complications, and survival were assessed. Materials included 156 patients with head and neck cancers treated palliatively with HDRBT and PDRBT in the Department of Otolaryngology of Poznan University of Medical Sciences and in the Department of Brachytherapy of Greater Poland Cancer Center from January 2002 to November 2008.RESULTS: Complete and partial remissions 6 months after finishing the treatment were achieved in 37.7% of patients, whereas survival rates 12 and 24 months after brachytherapy were estimated for 40% and 17%, respectively. The overall complications rate was 35%.CONCLUSIONS: Our results suggest that HDRBT and PDRBT constitute a safe alternative in the palliative treatment of patients with locally or regionally recurrent head and neck cancers with a relapse in a previously irradiated area, which were not qualified or rejected surgery. It gives a good palliative effect with acceptable complication rate. (C) 2012 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.